L9S.F Gyre Therapeutics, Inc.
- Market cap
- EUR 418M
- P/E
- -
- P/B
- 4.69x
- ROE
- -28.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is L9S.F undervalued?
Graham numberThe Graham number of Gyre Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gyre Therapeutics, Inc. fundamental analysis
No fundamental analysis for Gyre Therapeutics, Inc. yet.
Gyre Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Pha…
Full company profileGyre Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gyre Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 89.6M | 102M | 113M | 106M | 117M | 113M |
| Gross Profit | 85.6M | 97.5M | 109M | 102M | 111M | 106M |
| Operating Income | 30.1M | 9.20M | 19.2M | 16.2M | 11.5M | -29.5M |
| EBITDA | - | 10.3M | 20.3M | 17.8M | 14.0M | -26.0M |
| Net Income | 23.4M | 2.30M | -92.9M | 12.1M | 5.03M | -31.1M |
| EPS | 0.31 | 0.03 | -1.21 | 0.14 | 0.06 | -0.29 |
| Balance Sheet | ||||||
| Total Assets | 84.9M | 84.8M | 117M | 125M | 166M | 201M |
| Total Liabilities | 11.9M | 12.5M | 103M | 27.0M | 23.9M | 56.7M |
| Shareholders' Equity | 72.9M | 42.5M | -15.8M | 63.3M | 106M | 108M |
| Cash & Short-term Investments | 26.1M | 25.2M | 33.5M | 11.8M | 37.1M | 41.6M |
| Cash Flow | ||||||
| Operating Cash Flow | 20.8M | 10.7M | 25.9M | -3.64M | 1.01M | -23.4M |
| Capital Expenditure | 8.45M | 5.00M | 8.59M | 3.13M | 1.92M | 3.39M |
| Free Cash Flow | 12.3M | 5.68M | 17.3M | -6.77M | -913K | -26.8M |
| Ratios | ||||||
| ROE | 32.1% | 5.4% | - | 19.1% | 4.7% | -28.8% |
| ROA | 27.6% | 2.7% | -79.7% | 9.6% | 3.0% | -15.5% |
| Net Profit Margin | 26.2% | 2.3% | -81.9% | 11.4% | 4.3% | -27.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gyre Therapeutics, Inc. dividends
Gyre Therapeutics, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Gyre Therapeutics, Inc.
- Insiders 72.07%
- Institutions 8.33%
- Public & others 19.60%
- Shares outstanding 109M
- Free float 39.4M
Gyre Therapeutics, Inc. company profile
- Company name
- Gyre Therapeutics, Inc.
- Ticker
- L9S.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 625
- Fiscal year end
- December
- Address
- 12730 High Bluff Drive, San Diego, CA, United States, 92130
- Phone
- 858-284-0115
- Website
- gyretx.com
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Gyre Therapeutics, Inc. management
10- Mr. Thomas W. Eastling M.D.Chief Financial Officer · born 1959
- Mr. Weiguo YeChief Operating Officer · born 1978
- Ms. Ruoyu ChenChief Information Officer · born 1971
- Dr. Ying Luo Ph.D.CEO, President & Director · born 1965
- Dr. Yue Xiong Ph.D.Chief Scientific Officer & Director
- Mr. Joshua Bergmann J.D.General Counsel & Corporate Secretary
- Seth Goldblum M.B.A.Senior Vice President of Corporate Development
- Mr. Jialiang Wang Ph.D.Executive VP & GM
- Jing Liu Ph.D.Senior Vice President of Platform Chemistry
- Mark MarinoSenior Vice President of Clinical Development